Given the apparent involvement of TFAP2A in the MAPK pathway, the impact of TFAP2A overexpression on the responsiveness of tumour cells to osimertinib, a first-line targeted drug for NSCLC patients, was investigated. This evidence concerns the gene TFAP2A and neoplasm.